Biogen Inc

11. Juni 2026, 19:51 UTC

Biogen Inc is advancing as the biotechnology sector gains. Earlier in the session, shares pulled back from a high but resumed their upward trajectory.

10. Juni 2026, 19:36 UTC

Biogen Inc. is under investigation by Bronstein, Gewirtz & Grossman, LLC, following disappointing Phase 2 CELIA study results. Shares are trading lower amid ongoing scrutiny.

9. Juni 2026, 23:16 UTC

Biogen Inc. shares declined in after-market trading, moving lower since Tuesday's close. The asset remains above its 20-day moving average.

8. Juni 2026, 20:06 UTC

Biogen Inc. shares are lower amid negative sentiment over its Phase 2 CELIA study results, despite a recent upgrade to a Buy rating.

5. Juni 2026, 19:16 UTC

Biogen shares are gaining following FDA's Breakthrough Therapy Designation for salanersen in spinal muscular atrophy, despite pulling back from earlier session highs.

4. Juni 2026, 22:06 UTC

Biogen Inc. received FDA Breakthrough Therapy Designation for salanersen, aimed at treating spinal muscular atrophy, with shares trading higher in after-market hours.

3. Juni 2026, 20:03 UTC

Biogen Inc. announced fourteen abstracts accepted for presentation at upcoming nephrology congresses, contributing to higher trading shares amid positive market sentiment.

2. Juni 2026, 20:06 UTC

Biogen Inc. shares declined during Tuesday's session, continuing a trend of lower closes, amid broader weakness in the biotechnology sector.

1. Juni 2026, 19:26 UTC

Biogen shares are lower following positive Phase 3 trial results for dapirolizumab pegol, despite significant improvements in disease activity for lupus patients.

29. Mai 2026, 19:26 UTC

Biogen Inc. shares are trading lower today, reversing a recent trend of higher daily closes since Thursday's close. No specific news was identified.

28. Mai 2026, 20:06 UTC

Biogen Inc shares are lower, continuing a downward trend since Wednesday. No specific news was identified to explain today's movement.

27. Mai 2026, 20:06 UTC

RBC Capital raised its price target on Biogen Inc to $227, supporting shares' overall gain during Wednesday's trading amid positive pipeline developments.

26. Mai 2026, 19:56 UTC

Biogen Inc. shares are lower following concerns over the failure of its Parkinson's drug BIIB122 in a Phase 2b trial.

22. Mai 2026, 19:37 UTC

Biogen shares are higher following the Phase 2b LUMA study results for BIIB122, which showed over 90% kinase inhibition despite not meeting primary endpoints.

21. Mai 2026, 23:02 UTC

Biogen Inc. shares declined in after-market hours following the failure of its Parkinson's treatment, BIIB122, to meet key trial endpoints in the Phase 2b LUMA study.

20. Mai 2026, 23:51 UTC

Biogen Inc. shares are trading lower in after-market hours, reflecting broader market declines amid weak sentiment and macroeconomic factors affecting various sectors.

19. Mai 2026, 23:36 UTC

Biogen Inc shares are trading higher in after-market hours, showing a modest recovery from earlier losses amid broader market caution over inflationary pressures.

18. Mai 2026, 19:15 UTC

Biogen shares are lower amid negative sentiment from its CELIA trial results, which failed to meet primary endpoints, and ongoing investigations into potential securities violations.

15. Mai 2026, 19:56 UTC

Biogen completes $5.3 billion acquisition of Apellis Pharmaceuticals, enhancing its drug portfolio. Shares are trading higher amid positive analyst ratings and target price increases.

14. Mai 2026, 23:01 UTC

Biogen shares rose in after-market hours following positive topline results from the Phase 2 CELIA study on diranersen for early Alzheimer's disease.

13. Mai 2026, 19:31 UTC

Biogen shares are higher as executives discuss igan's competitive landscape and reaffirm commitment to bib091 for multiple sclerosis during the BofA Healthcare conference.

12. Mai 2026, 19:47 UTC

Biogen Inc gains momentum amid broader biotech sector rally. The company’s $850 million deal for felzartamab rights in Greater China boosts its growth prospects.

11. Mai 2026, 20:06 UTC

Biogen shares rise following FDA's three-month review extension for lecanemab-irmb. This marks a fifth consecutive daily gain, despite rising U.S. Treasury yields.

8. Mai 2026, 19:56 UTC

Biogen shares rise after FDA extends review for LEQEMBI. The new action date is August 24, 2026, allowing more time for data evaluation.

7. Mai 2026, 19:26 UTC

Biogen Inc maintains position above its 20-day moving average. Initial jobless claims rise unexpectedly, indicating mixed economic conditions amid today's modest trading.

4. Mai 2026, 19:36 UTC

Biogen Inc. shows slight recovery today, hovering near monthly highs. The SPDR S&P Biotech ETF's positive sentiment supports this uptick in the biotech sector.

1. Mai 2026, 21:01 UTC

Biogen Inc. shows steady after-hours trading, indicating reduced momentum. The stock remains above its 20-day moving average, reflecting strong recent performance.

30. Apr. 2026, 09:56 UTC

Biogen Inc sees slight decline despite surging Leqembi sales. The drug's promotion suggests potential revenue growth, impacting stock valuation discussions.